Hyaluronic acid in the evaluation of liver fibrosis in patients with hepatitis C on haemodialysis
Braz. j. infect. dis
;
14(4): 335-341, July-Aug. 2010. ilus, tab
Article
in English
| LILACS
| ID: lil-561203
ABSTRACT
BACKGROUND:
This study evaluated the role of HA as a marker of liver fibrosis in patients with hepatitis C on haemodialysis.METHODS:
This is a cross-sectional study in which 52 patients were divided into two groups Group 1 patients with hepatitis C and end-stage renal disease (ESRD) undergoing haemodialysis (n = 23); and Group 2 patients with hepatitis C without ESRD (n = 29). Plasma levels of HA were associated with histological data of the samples obtained by liver biopsy and classified by METAVIR group scoring system.RESULTS:
Higher plasma levels were significantly correlated to significant liver fibrosis (METAVIR > F2). In Group 1, the HA cutoff to discriminate significant fibrosis was 984.8 ng/mL, with accuracy, sensitivity and specificity of 80.8 percent, 83.0 percent, and 70.0 percent, respectively. In Group 2, the HA cutoff was 222.3 ng/mL, with accuracy, sensitivity and specificity of 74.5 percent, 70.0 percent, and 94.0 percent, respectively.CONCLUSION:
HA was an accurate noninvasive marker in predicting significant fibrosis in patients with hepatitis C on haemodialysis.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Hepatitis C, Chronic
/
Hyaluronic Acid
/
Liver Cirrhosis
Type of study:
Diagnostic study
/
Etiology study
/
Observational study
/
Prevalence study
/
Prognostic study
/
Risk factors
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
English
Journal:
Braz. j. infect. dis
Journal subject:
Communicable Diseases
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS